DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals 81

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 81

DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.

Drug Development 74

Drug Development Clinical Trials Drugs Therapies 74

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Packaging 59

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Nearly three million drug-resistant infections occur annually in the U.S.

Therapies 115

Therapies DNA Virus Clinical Trials 115

Drug Target Review

NOVEMBER 16, 2023

There is a substantial need for new therapies to treat drug-resistant infections without contributing to or perpetuating resistance; therefore, we are committed to developing highly effective treatment solutions that can be used against a broad range of bacterial infections.

Pharmaceuticals 105

Pharmaceuticals Therapies Clinical Trials Trials 105

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development?

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Advarra

AUGUST 10, 2023

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases.

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

PPD

DECEMBER 19, 2022

PPD, Thermo Fisher Scientific ’s clinical research business, surveyed more than 150 decision-making leaders at pharmaceutical and biotech companies around the globe to collect key insights on the state of the evolving drug development industry. The opportunity to leverage new technologies in drug development (e.g.,

Clinical Trials 52

Clinical Trials Drug Development Trials Clinical Research 52

PPD

AUGUST 28, 2024

For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. For many patients, involvement in oncology clinical trials represents a last hope for an effective therapy.

Trials 64

Trials Clinical Trials Therapies Drug Development 64

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Alta Sciences

OCTOBER 28, 2024

This comprehensive white paper provides an in-depth look at genome sequencing, proteomics, and functional characterization of the Sinclair Nanopig™, offering key insights for pharmaceutical and biopharmaceutical safety evaluations. Issue 41 of The Altascientist focuses on bioanalytical testing for immunomodulatory drugs.

Science 52

Science Clinical Trials Trials FDA 52

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.

Clinical Pharmacology 40

Clinical Pharmacology Laboratories Drug Development Pharmaceuticals 40

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

Therapies 72

Therapies Pharmaceuticals Disease Research 72

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Also in December, the company partnered with Atara Biotherapeutics to develop off-the-shelf T-cell immunotherapies for high mesothelin-expressing tumors. Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 81

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 81

The Pharma Data

OCTOBER 30, 2020

31, 2020 /PRNewswire/ — Promentis Pharmaceuticals, Inc. , a privately held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced that Dr. Chad E. About Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. MILWAUKEE , Oct. Source link.

Pharmaceuticals 52

Pharmaceuticals Therapies Drug Development Trials 52

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Clinical Development Pharmaceutical Companies Drug Development 98

Conversations in Drug Development Trends

OCTOBER 29, 2024

Increasingly, patients and patient-led organizations are playing a pivotal role in shaping drug development, underscoring the importance of collaboration between patient organizations, CROs, and pharmaceutical and biotechnology companies.

Clinical Research 72

Clinical Research Disease Research Clinical Trials 72

The Pharma Data

JUNE 2, 2022

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and oncology drug development expertise. Chief Executive Officer and Co-Founder of Immatics. “We FRCP, D.Phil.,

Therapies 52

Therapies Production Engineering Clinical Development 52

The Pharma Data

MAY 5, 2022

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia. 1 Clinical trials for new therapies in AML are becoming increasingly lengthy to complete based on the traditional clinical endpoint of survival.

Disease 52

Disease Clinical Trials Drug Development Pharmaceutical Companies 52

LifeSciVC

OCTOBER 13, 2022

This summer, approvals on both sides of the Atlantic – for beta thalassemia and cerebral adrenoleukodystrophy in the United States and for severe hemophilia A and aromatic L-amino acid carboxylase deficiency in Europe – show that regulators are likely open to green-lighting a range of emerging gene therapies.

Therapies 40

Therapies Disease Treatment Marketing 40

Drug Target Review

AUGUST 9, 2024

What is drug formulation? Drug formulation is the process of designing and producing a final medicinal product from an active pharmaceutical ingredient (API). 1 The goal is to create a dosage form that delivers the drug effectively to the intended site of action with optimal patient benefit and a good commercial value.

Science 59

Science Drugs Compliance Drug Development 59

The Pharma Data

NOVEMBER 1, 2020

Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company.

Therapies 52

Therapies Science Treatment Disease 52

Alta Sciences

OCTOBER 9, 2024

Dr. Setnik made the list of 100 honorees for her hands-on leadership and nearly 20 years of experience in clinical drug development, with a focus on abuse potential studies. Each winner represents the transformative impact of the pharmaceutical industry in their own unique way.

Clinical Pharmacology 40

Clinical Pharmacology Drug Development Science Clinical Trials 40

The Pharma Data

MARCH 22, 2021

Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with 177 Lu-PSMA-617. More than 15 dedicated early to late development and research programs underway to identify the next wave of radioligand therapies for cancer. About 177 Lu-PSMA-617.

Therapies 52

Therapies Treatment Trials Pharmaceutical Companies 52

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a commercial stage pharmaceutical company. acquired by Teva Pharmaceuticals in 2014.

Science 145

Science Disease FDA Approval Clinical Trials 145

PPD

SEPTEMBER 16, 2024

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. AI technologies are fueling drug discovery and asset and trial ROI optimization.

Clinical Development 52

Clinical Development Clinical Trials Clinical Research Trials 52

The Premier Consulting Blog

NOVEMBER 20, 2024

Process validation is a critical regulatory requirement in pharmaceutical manufacturing. Key considerations for concurrent process validation In cases where expediting the drug approval process is in the public’s best interest, the PPQ may be performed concurrently with commercial manufacturing.

Small Molecule 52

Small Molecule Drugs FDA Production 52

Alta Sciences

DECEMBER 13, 2023

Get Improved Bioavailability and Stability With This Dosage Form blussier Wed, 12/13/2023 - 22:36 HTML The choice of dosage form in drug development depends on various factors, such as the properties of the API, the therapeutic goals, and regulatory considerations.

Clinical Trials 40

Clinical Trials Compliance Drug Development Trials 40

Drug Target Review

DECEMBER 6, 2023

This report invites you to explore the latest breakthroughs in RNA-centric fields, from innovative proteolipid platforms with transformative potential in DNA-based vaccines, as presented by Dr John Lewis, to the remarkable journey of Sam Hasson in drug discovery, emphasising the challenges and opportunities in RNA-centric drug development.

RNA 52

RNA DNA Vaccine Drug Development 52

Drug Target Review

AUGUST 15, 2023

Prochownik, delved into the dual role of the Myc gene in both cancer development and ageing. The findings highlight the gene’s complex functions, opening up new avenues for cancer therapy and raising important considerations for future drug development.

Research 98

Research Pharmaceutical Companies Drug Development Therapies 98